Evidence map›Paper›PMID 25305503›Full record

ArticleJournal of cardiac failure2014

Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model.

Youhua Zhang, Eduard I Dedkov, Bianca Lee, Ying Li, Khusbu Pun, A Martin Gerdes

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiac failure, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Youhua ZhangDepartment of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York. Electronic address: yzhang49@nyit.edu.
Eduard I DedkovDepartment of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York.
Bianca LeeDepartment of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York.
Ying LiDepartment of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York.
Khusbu PunDepartment of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York.
A Martin GerdesDepartment of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York.
New York Institute of Technology · US

Funding

Low Thyroid function and myocardial infarctionR01HL103671 · NHLBI · NEW YORK INST OF TECHNOLOGY · PI GERDES, ANTHONY MARTIN · 2011 to 2015
$1.8M
NHLBI NIH HHS R01 HL103671NHLBI NIH HHS R01HL103671
6 · The paper itself

Abstract

backgroundHeart failure (HF) is associated with increased atrial fibrillation (AF) risk. Accumulating evidence suggests the presence of myocardial tissue hypothyroidism in HF, which may contribute to HF development. In a recent report we demonstrated that hypothyroidism, like hyperthyroidism, leads to increased AF inducibility. The present study was designed to investigate the effect of thyroid hormone (TH) replacement therapy on AF arrhythmogenesis in HF. METHODS AND

resultsMyocardial infarction (MI) was produced in rats by means of coronary artery ligation. Rats with large MIs (>40%) were randomized into L-thyroxine (T4; n = 14) and placebo (n = 15) groups 2 weeks after MI. Rats received 3.3 mg T4 (in 60-day release form) or placebo pellets for 2 months. Compared with the placebo, T4 treatment improved cardiac function and decreased left ventricular internal diameters as well as left atrial diameter. T4 treatment attenuated atrial effective refractory period prolongation (45 ± 1.5 ms in placebo group vs 37 ± 1.6 ms in T4 group; P < .01) and reduced AF inducibility (AF/atrial flutter/tachycardia were inducible in 11/15 rats [73%] in the placebo- vs 4/14 rats [29%] in the T4-treated group; P < .05). Arrhythmia reduction was associated with decreased atrial fibrosis but was not associated with connexin 43 changes.

conclusionsTo our knowledge this is the first study demonstrating that TH replacement therapy in HF attenuates atrial remodeling and reduces AF inducibility after MI-HF. Clinical studies are needed to confirm such benefits in human patients.

Indexed as

Hormone Replacement TherapyAnimalsAtrial FibrillationAtrial RemodelingDisease Models, AnimalElectrocardiographyFemaleHeart FailureMyocardial InfarctionRandom AllocationRatsRats, Sprague-DawleyReference ValuesRisk AssessmentSensitivity and SpecificityThyroxineThyroxinearrhythmogenesisAtrial fibrillationheart failurethyroid hormone

Identifiers

PMID25305503
PMCPMC4250313
OpenAlexW1980599980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.